Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

por Kavakli, K, Yang, R, Rusen, L, Beckmann, H, Tseneklidou-Stoeter, D, Maas Enriquez, M
Publicado 2015

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

por Santagostino, Elena, Kenet, Gili, Fischer, Kathelijn, Biss, Tina, Ahuja, Sanjay, Steele, MacGregor, Martínez, M., Male, C., van Geet, C., Mondelaers, V., Kaleva, V., Stoyanova‐Deleva, A., Bobev, D., Blanchette, V., Zanon, E., Gagliano, F., Rageliene, L., Peters, M., Mlynarski, W., Badowska, W., Serban, M., Rusen, L., Uscatescu, V., Will, A., Payne, J., Tunstall, O., Kerlin, B., Gruppo, R., Eyster, M. E., Ducore, J., Schwartz, J.
Publicado 2020